Market research
CLSN Celsion Corp
NASDAQ USD Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- 27
- Dividend yield
- 0.0%
- Beta
- 2.26
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology & Medical Research
- ISIN
- Not available
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- 27
- Dividend yield
- 0.0%
- Beta
- 2.26
About
About Celsion Corp
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
Research context
Celsion Corp appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology & Medical Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the CLSN discussion.
5 years, 6 months ago
Celsion Corporation is currently in a long term uptrend where the price is trading 1.0% above its 200 day moving average.
From a valuation standpoint, the stock is 93.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 93.3.
Celsion Corporation's total revenue sank by 0.0% to $125K since the same quarter in the previous year.
Its net income has increased by 2.9% to $-3M since the same quarter in the previous year.
Finally, its free cash flow grew by 33.6% to $-4M since the same quarter in the previous year.
Based on the above factors, Celsion Corporation gets an overall score of 4/5.